Klivira
Request demo

Aetna Biktarvy Prior Authorization: Streamlining HIV Therapy Access

Navigating Aetna Biktarvy prior authorization can be complex, but Klivira provides the automation and connectivity needed to streamline approvals for this critical HIV-1 medication.

For revenue cycle directors and prior authorization coordinators, efficient management of high-volume specialty drug PAs is paramount. Biktarvy, a key antiretroviral, frequently requires prior authorization across Aetna's commercial, Medicare Advantage, and Medicaid managed care plans, demanding precise workflow execution to ensure timely patient access.

Understanding Aetna's Prior Authorization Requirements for Biktarvy

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a widely used single-pill regimen for HIV-1 treatment. As a high-cost specialty medication, it is consistently subject to prior authorization by Aetna to ensure medical necessity and adherence to formulary guidelines. Providers must be prepared to demonstrate clinical criteria outlined in Aetna's utilization management policies.

Aetna's Submission Channels for Biktarvy Prior Authorizations

Since Biktarvy is typically a pharmacy-benefit drug, Aetna manages its prior authorization through CVS Caremark, Aetna's PBM. Submissions for outpatient retail pharmacy benefit PAs route via established ePA partners such as CoverMyMeds or Surescripts. For specific mail-order or case-managed scenarios, direct submission through CVS Caremark's provider portal may be required.

Aetna Clinical Policy Bulletins and Step Therapy for Antiretrovirals

Aetna's medical necessity criteria, including any step therapy requirements for antiretroviral medications like Biktarvy, are published within their Clinical Policy Bulletins (CPBs). These CPBs are versioned and dated, serving as the canonical source for specific clinical indications, dosing, and prerequisite therapies. Klivira's platform helps integrate these policy requirements directly into your PA workflow, reducing manual policy lookups.

Optimizing Turnaround Times for Aetna Biktarvy PAs

Prior authorization turnaround times for Biktarvy under Aetna plans are influenced by state regulations, NCQA accreditation standards, and, for Medicare Advantage and Medicaid plans, CMS-0057-F. This rule mandates 72-hour decisions for standard PA and 24-hour for expedited requests in impacted lines of business. Klivira automates submission and status checks, helping clinics align with these critical timeframes and reduce delays in patient care.

Common Denial Reasons and Appeal Pathways for Biktarvy with Aetna

Typical denial reasons for Biktarvy prior authorizations from Aetna include insufficient documentation of medical necessity, failure to meet step therapy requirements, or off-label use without compendium support. Should a denial occur, Aetna's appeal pathway generally includes reconsideration, peer-to-peer review, and formal appeals. Klivira supports robust denial management by providing tools for documentation organization and efficient submission of appeals.

Klivira's Integration with Aetna's Prior Authorization Ecosystem

Klivira integrates with your EMR to automate the submission of Aetna Biktarvy prior authorizations. By connecting to Aetna's ePA partners like CoverMyMeds and Surescripts, and supporting X12 278 transactions for medical benefit PAs where applicable, Klivira ensures that your requests are routed efficiently. This reduces manual data entry, minimizes errors, and provides real-time status updates, freeing your team to focus on patient care.

Frequently asked questions

How do I submit an Aetna Biktarvy prior authorization?

For pharmacy-benefit drugs like Biktarvy, Aetna's prior authorizations are processed by CVS Caremark. Submissions typically occur through ePA partners such as CoverMyMeds or Surescripts. Klivira integrates with these systems to automate the submission process directly from your EMR.

What are common reasons for Aetna Biktarvy PA denials?

Common denial reasons for Biktarvy PAs with Aetna include insufficient clinical documentation to establish medical necessity, failure to meet specific step therapy criteria, or cases where the prescribed use does not align with Aetna's Clinical Policy Bulletins (CPBs).

Does Aetna require step therapy for Biktarvy?

Aetna may require step therapy for Biktarvy, as detailed in their applicable Clinical Policy Bulletins (CPBs) for antiretroviral medications. These policies outline specific prerequisite therapies or clinical conditions that must be met before Biktarvy is authorized. Always consult the most current CPB.

What is the typical turnaround time for an Aetna Biktarvy prior authorization?

Turnaround times vary based on plan type and urgency. For Aetna's Medicare Advantage and Medicaid plans, CMS-0057-F mandates 72 hours for standard and 24 hours for expedited requests. For commercial plans, state regulations and NCQA standards (e.g., 15 days for non-urgent pre-service) apply.

Which Aetna entity handles Biktarvy prior authorizations?

Prior authorizations for pharmacy-benefit drugs like Biktarvy are handled by CVS Caremark, which is Aetna's Pharmacy Benefit Manager (PBM). For medical-benefit PAs, Aetna routes requests through the Availity provider portal or X12 278 transactions.

Related coverage

Other biktarvy prior authorization by payer

Other biktarvy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo